Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.01 USD | +5.24% | +18.50% | +124.63% |
20/03 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
20/03 | Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 25
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 01/11/01 |
Thomas Sciascia
FOU | Founder | 70 | 01/11/01 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 09/21/09 |
Danine Summers
CTO | Chief Tech/Sci/R&D Officer | - | 09/21/09 |
David J. Clark
CTO | Chief Tech/Sci/R&D Officer | 59 | 14/22/14 |
Katie McManus
IRC | Investor Relations Contact | - | - |
Katherine Takaki
LAW | General Counsel | - | - |
Farrell Simon
PRN | Corporate Officer/Principal | 42 | 01/23/01 |
Comptroller/Controller/Auditor | - | 12/21/12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 10/18/10 |
James Cassella
BRD | Director/Board Member | 69 | 13/20/13 |
Jennifer Good
FOU | Founder | 59 | 01/11/01 |
Director/Board Member | 60 | 29/20/29 | |
Director/Board Member | 64 | 01/17/01 | |
Director/Board Member | 59 | 01/17/01 | |
David Meeker
CHM | Chairman | 69 | 01/17/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 68,960,167 | 68,077,718 ( 98.72 %) | 0 | 98.72 % |
Company contact information
Trevi Therapeutics, Inc.
195 Church Street 14th floor
06510, New Haven
+
http://www.trevitherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+124.63% | 212M | |
-1.65% | 103B | |
+6.75% | 101B | |
+5.71% | 23.07B | |
-12.60% | 22.23B | |
-9.70% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- TRVI Stock
- Company Trevi Therapeutics, Inc.